Osteoporosis therapeutics: recent developments at ASBMR.
作者信息
Mallarkey Gordon, Reid David M
机构信息
Sage Publications Ltd, 1 Oliver's Yard, 55 City Road, London EC1Y 1SP, UK.
Emeritus Professor of Rheumatology, University of Aberdeen, Medical School, Foresterhill, Aberdeen, UK.
出版信息
Ther Adv Musculoskelet Dis. 2016 Feb;8(1):3-7. doi: 10.1177/1759720X15623489.
Abstract
摘要
相似文献
1
Osteoporosis therapeutics: recent developments at ASBMR.
Ther Adv Musculoskelet Dis. 2016 Feb;8(1):3-7. doi: 10.1177/1759720X15623489.
2
[ASBMR 2010 report. Meeting report on the ASBMR: clinical topics in ASBMR 2010 at Toronto].
Clin Calcium. 2011 Jan;21(1):112-5.
3
[ASBMR 2012 Report. Meeting report on the ASBMR. The battle between new and old medicine for the treatment of osteoporosis].
Clin Calcium. 2013 Jan;23(1):105-8.
4
[ASBMR 2010 report. Meeting report on the ASBMR. Present and future of the treatment of osteoporosis].
Clin Calcium. 2012 Jan;22(1):114-8.
5
[ASBMR 2009 Report. Meeting report on the ASBMR. ASBMR topics].
Clin Calcium. 2010 Jan;20(1):108-11.
6
[ASBMR 2009 Report. Meeting report on the ASBMR. ASBMR topics].
Clin Calcium. 2010 Jan;20(1):112-5.
7
[ASBMR 2013 REPORT. Meeting Report on the ASBMR. Topics for basic or clinical research in ASBMR 2013].
Clin Calcium. 2014 Jan;24(1):114-8.
8
[ASBMR 2011 report. Meeting report on the ASBMR. Clinical topics in ASBMR 2011 at San Diego - vitamin D and calcium -].
Clin Calcium. 2012 Jan;22(1):111-3.
9
[ASBMR Topics from clinical research concerning bone and mineral metabolism other than osteoporosis.].
Clin Calcium. 2019;29(1):116-120.
10
[ASBMR 2006 Report. Pathophysiology and diagnosis of osteoporosis].
Clin Calcium. 2007 Jan;17(1):96-100.
引用本文的文献
1
Icariin Exerts Estrogen-Like Actions on Proliferation of Osteoblasts in Vitro via Membrane Estrogen Receptors-Mediated Non-nuclear Effects.
Iran J Pharm Res. 2022 Aug 28;21(1):e127000. doi: 10.5812/ijpr-127000. eCollection 2022 Dec.
2
Management of adynamic bone disease in chronic kidney disease: A brief review.
J Clin Transl Endocrinol. 2016 Jul 25;5:32-35. doi: 10.1016/j.jcte.2016.07.002. eCollection 2016 Sep.
本文引用的文献
1
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
Osteoporos Int. 2015 Dec;26(12):2773-83. doi: 10.1007/s00198-015-3234-7. Epub 2015 Jul 23.
2
Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.
Osteoporos Int. 2015 Feb;26(2):699-712. doi: 10.1007/s00198-014-2944-6. Epub 2014 Nov 29.
3
Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study.
J Bone Miner Res. 2015 Jan;30(1):39-45. doi: 10.1002/jbmr.2315.
4
Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
J Clin Endocrinol Metab. 2014 May;99(5):1694-700. doi: 10.1210/jc.2013-4440. Epub 2014 Feb 11.
5
Romosozumab in postmenopausal women with low bone mineral density.
N Engl J Med. 2014 Jan 30;370(5):412-20. doi: 10.1056/NEJMoa1305224. Epub 2014 Jan 1.
6
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.
Lancet. 2013 Jul 6;382(9886):50-6. doi: 10.1016/S0140-6736(13)60856-9. Epub 2013 May 15.
Zotero 插件